HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of isoflurane and caspase inhibition reduces cerebral injury in rats subjected to focal cerebral ischemia.

AbstractBACKGROUND:
Recent data indicate that the neuroprotective efficacy of isoflurane is not sustained. Delayed neuronal death, mediated in part by apoptosis, contributes to the gradual increase in the size of the infarction. These data suggest that isoflurane may not be able to inhibit delayed neuronal death. The prevention of apoptosis by a caspase inhibitor might provide neuroprotection in addition to that provided by isoflurane. The current study was conducted to determine whether isoflurane-mediated neuroprotection can be made more durable with the administration of z-VAD-fmk, a nonspecific caspase inhibitor.
METHODS:
Fasted Wister rats were allocated to awake-zVAD, awake-vehicle, isoflurane-zVAD, or isoflurane-vehicle groups (n = 16/group). Animals were subjected to focal ischemia for 60 min by filament occlusion of the middle cerebral artery. In the awake groups, isoflurane was discontinued after occlusion of the middle cerebral artery. In the isoflurane groups, isoflurane anesthesia was maintained at 1.5 minimum alveolar concentration during occlusion of the middle cerebral artery. Before and after ischemia, daily injections of z-VAD-fmk or vehicle were administered into the lateral cerebral ventricle for 14 days. Neurologic assessment was performed 14 days after ischemia. The volume of cerebral infarction and the number of intact neurons in the periinfarct cortex were determined by image analysis of hematoxylin and eosin-stained coronal brain sections.
RESULTS:
Infarction volume was less in the isoflurane-zVAD group (23 +/- 11 mm, mean +/- SD) than in isoflurane-vehicle, awake-vehicle, and awake-zVAD groups (82 +/- 31, 86 +/- 31, and 59 +/- 25 mm, respectively; P < 0.05). In comparison with the awake-vehicle and isoflurane-vehicle groups, the administration of z-VAD-fmk significantly decreased infarction volume (P < 0.05). The infarction volume between the awake-vehicle and isoflurane-vehicle groups was not different. The number of intact neurons within the periinfarct cortex was significantly less in the awake-vehicle group than in the other three groups (P < 0.05). The isoflurane-zVAD group demonstrated better neurologic function than the awake-vehicle group (P < 0.05).
CONCLUSION:
These findings are consistent with the premise that ongoing delayed neuronal death, in part mediated by apoptosis, contributes to the progression of cerebral infarction during the recovery period, and its inhibition can provide sustained neuroprotection.
AuthorsSatoki Inoue, John C Drummond, Daniel P Davis, Daniel J Cole, Piyush M Patel
JournalAnesthesiology (Anesthesiology) Vol. 101 Issue 1 Pg. 75-81 (Jul 2004) ISSN: 0003-3022 [Print] United States
PMID15220774 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Amino Acid Chloromethyl Ketones
  • Anesthetics, Inhalation
  • Caspase Inhibitors
  • Enzyme Inhibitors
  • Neuroprotective Agents
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • Isoflurane
Topics
  • Amino Acid Chloromethyl Ketones (therapeutic use)
  • Anesthetics, Inhalation (therapeutic use)
  • Animals
  • Blood Gas Analysis
  • Brain (pathology)
  • Brain Ischemia (drug therapy, pathology)
  • Caspase Inhibitors
  • Enzyme Inhibitors (therapeutic use)
  • Hemodynamics (drug effects, physiology)
  • Infarction, Middle Cerebral Artery (pathology, prevention & control)
  • Isoflurane (therapeutic use)
  • Male
  • Neurons (pathology)
  • Neuroprotective Agents
  • Rats
  • Rats, Wistar

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: